

WAGO 2025 Annual Meeting
June 19-21, 2025
Colorado Springs, CO

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** *(formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations**.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. "Relevant" financial relationships are financial transactions (in any amount) occurring within the **past 24 months** that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An "**ineligible company**" is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

NAME	Individual's Role(s) in Activity	Nothing To Disclose	Name of Ineligible Company(s)	Nature of Relevant Financial Relationship(s)
Planning Disclosures				
Castellano, Tara, MD	Planner		GSK; Bristol Meyers Squibb Foundation; GOG Foundation	Consultant (GSK) Grant Awardee (Bristol Myers Squibb Foundation) Travel Award (GOG Foundation)
Chase, Dana, MD	Moderator		AstraZeneca; ImmunoGen; GSK; Clovis	Consultant
Chapman, Jocelyn, MD	Moderator	X		
Cohen, Josh, MD	Planner	X		
Dexter, Julia, MD	Planner/ Moderator	X		
Holman, Laura, MD	Moderator	X		
Holschneider, Christine, MD	Planner	X		
Huang, Dandi, MD	Moderator	X		
Kim, Kenneth, MD	Planner	X		
Littell, Ramey, MD	Moderator	X		
Manuel, Michael, MD	Moderator	X		
McHale, Michael, MD	Planner		Eisai	Consultant
Norquist, Barbara, MD	Moderator	X		
Prendergast, Emily, MD	Moderator		AstraZeneca	Consultant
Sinno, Abdulrahman, MD	Planner/ Moderator	X		
Urban, Renata, MD	Planner	X		
Walsh, Christine, MD	Planner/ Moderator		Regeneron; OncLive	Advisory Board (Regeneron) Meeting Faculty (OncLive)
Washington, Christina, MD	Planner		AstraZeneca	Advisory board

FACULTY DISCLOSURE INFORMATION

Zamorano, Abigail, MD, MPH	Moderator		Abbvie	Consultant
Speaker Disclosures				
Ayoub, Natalie, MD	Speaker	X		
Bartholomew, Alexandra	Speaker	X		
Beshar, Isabel, MD	Speaker	X		
Bitler, Benjamin, PhD	Speaker	X		
Bolten, Katherine, MD	Speaker	X		
Browning, Anne, PhD, MA	Speaker	X		
Bruegl, Amanda, MD	Speaker		AbbVie	Consultant
Cervantes, Jorge, BS	Speaker	X		
Cham, Stephanie, MD, MS	Speaker	X		
Chase, Dana, MD	Speaker		AstraZeneca; ImmunoGen; GSK; Clovis	Consultant
Chaudhari, Sonal, MD	Speaker	X		
Chebat, Alissa, MD	Speaker	X		
Chen, Grace, MD	Speaker	X		
Conway, Angela, MD, MS	Speaker	X		
Dexter, Julia, MD	Speaker	X		
Doan, Allen, MD, MPH	Speaker	X		
Ehimiaghe, Eseohi, MD	Speaker	X		
Erdemoglu, Evrim, MD	Speaker	X		
File, Brittany, MD	Speaker	X		
Fuh, Katherine, MD, PhD	Speaker		Aravive; AstraZeneca; GlaxoSmithKline; Immunogen; Share 3% of the 33% of the investigators	Consultant (Aravive; AstraZeneca; GlaxoSmithKline; Immunogen) Intellectual Property -Patent Share 3% of the 33% of the investigators)
Gomez, Karina, MD, PhD	Speaker	X		
Kleinberg, Katherine, DO	Speaker	X		
Liang, Margaret, MD	Speaker		Merck; Foundation for Women's Cancer; Intuitive	Research Grant (Merck, Foundation for Women's Cancer) Travel to training workshops (Intuitive)
Marta, Patrick, MD	Speaker	X		
Melo, Valeria, MD	Speaker	X		
Meyer, Larissa A., MD, MPH	Speaker		AstraZeneca; Abbvie; Merck; Johnson&Johnson; Denali; Invitae; Crispr	Research support (AstraZeneca; Merck) Consultant (Abbvie) Travel support (AstraZeneca) Stock: Johnson&Johnson, Denali, Invitae, Crispr
Minalt, Nicole, MD	Speaker	X		
Nguyen, Christine, MD	Speaker	X		
Rimel, Bobbie J., MD	Speaker		AstraZeneca; GSK; ImmunoGen; Merck; Tempus	Consultant (Tempus) Advisory Board Member (ImmunoGen, Merck, GSK, AstraZeneca)
Ritchie, Julia, MD	Speaker	X		
Ryu, Megan	Speaker	X		
Sammouri, Julie, MD	Speaker	X		
Shachar, Eliya, MD	Speaker	X		
Shin, Ashley	Speaker	X		
Tannous, Andrew, MD	Speaker	X		
Walker, Allison, MD	Speaker	X		
Wormack, Leah, MD MS	Speaker	X		
Zamorano, Abigail, MD, MPH	Speaker		Abbvie	Consultant
Zello, Lily	Speaker	X		
Zhang, Yingao, MD, MS	Speaker	X		

FACULTY DISCLOSURE INFORMATION

Engbert, Holley	Staff	X		
Rush, Heather	Staff	X		
Small, Michelle N, MPH	Reviewer /Staff	X		
Angeles Alvarez-Secord, MD	Reviewer/ Edu-Chair		AZ, Abbvie; Aravive; Clovis, Eisai, Ellipses Pharma, Roche/Genentec; GSK; I-MAB Biopharma; Immunogen; Karyopharm; Merck; Mersana; Seagen; VBL Therapeutics; Gilead; Oncoquest/Canaria Bio	Research funds to Institution (AZ, Abbvie; Aravive; Clovis; Eisai; Ellipses Pharma; Roche/Genentec; GSK; I-MAB Biopharma; Immunogen; Karyopharm; Merck; Mersana; Seagen; VBL Therapeutics; Zentalis; Oncoquest/Canaria Bio) Adboard (Abbvie) Uncomp AdBoard (Gilead; Oncoquest/Canaria Bio; Aravive; VBL) Steering Committee (Aravive; VBL; Oncoquest/Canaria Bio)